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Malignant pleural mesothelioma: time for translational research
Recently in The Lancet Oncology,
Fennell and Rudd1 reviewed the present
state of apoptosis biology in malignant
pleural mesothelioma (MPM). 
Two properties are essential for cell
survival during MPM carcinogenesis:
cell division and resistance to apop-
tosis.1 In particular, multiple somatic
events are needed for MPM genesis. Of
interest is the finding that BCL2 is
overexpressed and encodes two death
regulators (BCLXL, a protective factor
and BCLXS, a proapoptotic factor).2
MPM cells undergo an epithelial
transition process that involves WT1,
which is known to play a part in
regulation of BCL2; and epithelial
tumour cells typically develop defects
in the mitotic apparatus, probably
because of defective expression of
regulators such as aurora-A and PLK.3
The epithelial transition in MPM cells
involves faulty gene activation and
genomic imbalance; in fact, MPM cells
overexpress factors that affect cell
division (eg, SV40 large T antigen,
survivin, and P53).4
Cytological studies have shown that
MPM cells are genomically unstable
(eg, loss or gain of chromosomes, no
apoptosis, and limitless cell replication
and expansion). Furthermore, cytogen-
etic studies show changes in the
karyotype, although none is specific for
MPM. 
Transduction experiments5 suggest
that heterogeneous alterations in MPM
cells can be targeted pharmacologically
with some effectiveness but more
comprehensive investigations of the
cell-cycle checkpoints are needed to
improve target selection. 
The P53 paralogous genes P63 and
P73 encode isoforms that either induce
or suppress apoptosis.6 The suppression
isoforms DNP63 and DNP73 can be
activated by DNA-damaging agents
through a P53-dependent pathway
(Cesario A, unpublished data). Further-
more, the DNP73 promoter can be
activated by members of the NFB
transcription-factor family and by the
RAS-RAF pathway. 
These observations suggest a new
framework in which activation of the
RAS and NFB pathways in MPM cells
could, in part, over-ride the cell-cycle
checkpoints, and thus lead to apoptotic
resistance through transcriptional acti-
vation of DNP73 isoforms. 
Other evidence to support a role for
P63 and P73 in MPM checkpoint
dysfunction is the physical and
functional interaction between these
proteins, and the putative, over-
expressed oncosuppressor WT1.6
Furthermore, data7 from our group
have showed that MPM expresses a
cholinergic system involved in the
regulation of both cell growth and the
apoptotic machinery.
These data now need to be recon-
ciled to construct preclinical models
and to approach clinical research from
a translational perspective. 
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Authors’ reply
Cesario and colleagues have high-
lighted the potential contribution of
defective cell-cycle regulation to
apoptosis resistance in MPM. 
Teleologically, suppression of
mitochondrial outer-membrane per-
meabilisation (MOMP), mitochonrial
inner-membrane permeabilsation
(MIMP), or caspases, by neoplastic
cells is an effective way to promote
survival. Cesario and co-workers have
postulated that the antiapoptotic pro-
teins DNP63 and DNP73 mediate
apoptosis resistance, and are constitu-
tively transactivated by NFkB and
RAS-RAF pathway activation in
MPM. Although plausible, this
mechanism is unsubstantiated. These
proteins regulate core-apoptosis
signalling directly at the premito-
chondrial level. DNP73 inhibits the
proapoptotic action of the BH3-only
proapoptotic proteins, PUMA and
BAX. As a consequence, DNP73 also
regulates MOMP. Furthermore, P53
mediates apoptosis by direct induc-
tion of MOMP via activation of
PUMA or by upregulation of BAX.
DNA damage also results in trans-
location of histone H1.2 to the outer
mitochondrial membrane, and is
crucial for induction of MOMP. 
Cholinergic activation of the
mitogen-activated kinase pathway in
MPM (via 7 nicotinic acetylcholine
receptors), directly regulates signalling
to the core-apoptosis pathway via
phosphorylation of BAD on serine
112, leading to its inactivation and
inability to displace BAK from BCLXL
on the outer mitochondrial mem-
brane. 
These diverse premitochondrial
antiapoptotic mechanisms indirectly
regulate MOMP, MIMP, and APAF1
apoptosome-dependent caspase activ-
ation, processes that are sensitive to
downstream inhibition in MPM by
BCLXL and various members of the
IAP family. This inhibition is
important because it suggests that
effective strategies could be developed
to reverse antiapoptotic pathways.
Premitochondrial death-agonist strat-
egies, directed at the targets suggested
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by Cesario and colleagues, would need
to overcome several checkpoints
before activating caspases, and could
be blocked by inactivation of BAX,
BAK, MOMP, MIMP, or caspases.
Physiological disruption of IAP bin-
ding to caspases via release of
SMAC/DIABLO and OMI/HtrA2 can
be mimicked by SMAC peptide, or
mimetics, capable of synergising with
conventional or new premito-
chondrial apoptosis inducers. Such
approaches could be used to reverse
repression of the MPM caspase
pathway in a tumour-specific manner.
Dean Fennell and Robin Rudd
Department of Medical Oncology, St
Bartholomew’s Hospital, London, UK.
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Professional skills and shared consent in paediatric research
In a recent essay,1 Massimo and co-
authors stressed that informed
consent in paediatric research should
be managed as a negotiated process of
shared consent. They also advocated a
role for appropriate training of future
paediatricians to preserve and pro-
mote the child’s best interest. As 
a paediatric oncologist, paediatrics
teacher, and chair of an ethics com-
mittee in France, I offer another
perspective.
The French academic curriculum
has two obvious deficiencies: first, the
paediatric curriculum is centred
mainly on pathology and therapeutics,
with very little consideration of
communicative skills, relational beha-
viour, or reflection on ethics; and
second, paediatric trainees who aim to
reach an academic position, which is
determined mainly by the production
of research papers, follow an addi-
tional research curriculum that is
supposed to give them an adequate
investigative ability. In fact, this
training is focused on fundamental
research with very little attention to
clinical research and the special
requirements associated with paedia-
tric studies. As a result, competence to
design and manage a clinical research
programme involving children is often
self-acquired. I would advocate that
paediatric trainees need to be provided
with a coherent curriculum, based on
activities actually needed in their
future profession and practice. In
other words, paediatricians need to be
better prepared to do clinical research
in children.
The ethics committee that I chair
is often concerned about the wide
range of abilities between investigators
to write adequate patient information
and consent documents. This concern
highlights a major role for ethics
committees in protection of patients
and volunteers enrolled in trials. As a
general rule, ethics committees have a
mix of members from different back-
grounds, such as care-givers, ethicists,
social workers, lawyers, and patients.
This diversity is an important asset
and gives the committee a rich depth
of experience and knowledge. But, this
particularity is often misunderstood
by investigators. Teachers and trainees
should be made aware that ethics
committees can be a potentially useful
educational resource. 
Most paediatric study groups run
activities under the auspices of
paediatric societies2 or organisations,3
and are often involved in the
formulation of guidelines for good
clinical practice in paediatric research.
However, although these guidelines
increase awareness of important issues
within the paediatric community,
their implementation is not well
assessed.4
Finally, in 2001, the European
Union produced a directive,5 appli-
cable to each member state from May,
2004, that detailed new rules on good
clinical practice for all trials involving
children and for investigation of
medicinal products. In particular the
directive stated several key points
related to informed consent. First,
“consent must represent the minor’s
presumed will”; second, “the minor
has received information, according to
its capacity of understanding, from
staff with experience with minors,
regarding the trial, the risks, and the
benefits”; third, “the explicit wish of a
minor who is capable of forming an
opinion and assessing this information
to refuse participation or to be
withdrawn from the clinical trial at
any time is considered by the
investigator”; fourth, “the Ethics
Committee, with paediatric expertise
or after taking advice in clinical,
ethical, and psychosocial problems in
the field of paediatrics, has endorsed
the protocol”; and fifth, “the interests
of the patient always prevail over those
of science and society”. This directive
constitutes major progress in paedi-
atric research in European countries
and it will be important to ensure that
trainees are made fully aware of their
responsibilities in view of this new law.
The paediatric community now
needs to find a way to balance the
promotion and preservation of a
child’s best interests with the training
and professional activities of paedia-
tricians. The notion of shared consent
proposed by Massimo and co-authors1
will undoubtedly contribute to this
challenge.
Jean-Louis Bernard
Paediatric Oncology Department, La
Timone Children’s Hospital, Marseille,
France; and Consultative Committee of
Protection of the People in Biomedical
Research, Paris, France.
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